Pneumococcal conjugate vaccines: emerging clinical information and its implications

References

• US Centers for Disease Control and Prevention. Preventing pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR49(RR-9), 1–35 (2000).
   PubMedGoogle Scholar
• Ghaffar F. The safety of 7-valent pneumococcal conjugate vaccine. Expert Opin. Drug Safety.4(4), 631–636 (2005).
   PubMedGoogle Scholar
• Wise RP, Iskander J, Pratt RD et al. Postlicensure safety surveillance for 7-valent pneumococcal conjugate vaccine. JAMA292(14), 1702–1710 (2004).
   PubMed Web of Science ®Google Scholar
• Mbelle N, Huebner RE, Wasas AD, Kimura A, Chang I, Klugman KP. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. J. Infect. Dis.180, 1171–1176 (1999).
   PubMed Web of Science ®Google Scholar
• Buttery JP, Riddell A, McVernon J et al. Immunogenicity and safety of a combination pneumococcal-meningococcal vaccine in infants: a randomized controlled trial. JAMA293(14), 1751–1758 (2005).
   PubMed Web of Science ®Google Scholar
• Anderson EL, Kennedy DJ, Geldmacher KM, Donnelly J, Mendelman PM. Immunogenicity of heptavalent pneumococcal conjugate vaccine in infants. J. Pediatr.128(5), 649–653 (1996).
   PubMed Web of Science ®Google Scholar
• Puumalainen T, Zeta-Capeding MR, Käyhty H et al. Antibody response to an eleven valent diphtheria- and tetanus-conjugated pneumococcal conjugate vaccine in Filipino infants. Pediatr. Infect. Dis. J.21(4), 309–314 (2002).
   PubMedGoogle Scholar
• Nurkka A, Joensuu J, Henckaerts I et al. Immunogenicity and safety of the eleven valent pneumococcal polysaccharide-protein D conjugate vaccine in infants. Pediatr. Infect. Dis. J.23(11), 1008–1014 (2004).
   PubMed Web of Science ®Google Scholar
• Daum RS, Hogerman D, Rennels MB et al. Infant immunization with pneumococcal CRM197 vaccines: effect of saccharide size on immunogenicity and interactions with simultaneously administered vaccines. J. Infect. Dis.176, 445–455 (1997).
   PubMed Web of Science ®Google Scholar
• Leach A, Ceesay SJ, Banya WAS, Greenwood BM. Pilot trial of a pentavalent pneumococcal polysaccharide/protein conjugate vaccine in Gambian infants. Pediatr. Infect. Dis. J.15(4), 333–339 (1996).
   PubMed Web of Science ®Google Scholar
• Käyhty H, Åhman H, Rönnberg P-J, Tillkainen R, Eskola J. Pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine is immunogenic in infants and children. J. Infect. Dis.172, 1273–1278 (1995).
   PubMed Web of Science ®Google Scholar
• Dagan R, Melamed R, Zamir O, Leroy O. Safety and immunogenicity of tetravalent pneumococcal vaccines containing 6B, 14, 19F and 23F polysaccharides conjugated to either tetanus toxoid or diphtheria toxoid in young infants and their boosterability by native polysaccharide antigens. Pediatr. Infect. Dis. J.16(11), 1053–1059 (1997).
   PubMed Web of Science ®Google Scholar
• Whitney CG, Farley MM, Hadler J et al. Decline in invasive pneumococcal disease after introduction of protein-polysaccharide conjugate vaccine. N. Engl J. Med.348(18), 1737–1746 (2003).
   PubMed Web of Science ®Google Scholar
• Reingold A, Hadler J, Farley MM et al. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease – United States, 1998–2003. MMWR54(36), 893–897 (2005).
   Google Scholar
• Flannery B, Schrag S, Bennett NM et al. Impact of childhood vaccination on racial disparities in invasive Streptococcus pneumoniae infections. JAMA291(18), 2197–2203 (2004).
   PubMedGoogle Scholar
• Hennessy TW, Singleton RJ, Bulkow LR et al. Impact of heptavalent pneumococcal conjugate vaccine on invasive disease, antimicrobial resistance and colonization in Alaska natives: progress towards elimination of a health disparity. Vaccine23, 5464–5473 (2005).
   PubMed Web of Science ®Google Scholar
• Hennessy TW, Singleton RJ, Bulkow L et al. Increase in invasive pneumococcal disease in Alaskanative children due to serotypes not in the heptavalent pneumococcal conjugate vaccine. 5th International Symposium on Pneumococci and Pneumococcal Diseases, Alice Springs, Australia, 2–6 April, 60, Abstract SY2.06, 2006.
   Google Scholar
• Poehling KA, Talbot TR, Griffin MR et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA295(14), 1668–1674 (2006).
   Google Scholar
• Lexau CA, Lynfield R, Danila R et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA294(16), 2043–2051 (2005).
   PubMed Web of Science ®Google Scholar
• Moore MR, Pilishvili T, Bennett NM et al. Age-specific trends in invasive pneumococcal disease among adults: evidence for indirect effects of conjugate use among children – selected US sites, 1998–2004. 5th International Symposium on Pneumococci and Pneumococcal Diseases, Alice Springs, Australia, 2–6 April, 190, Abstract PO4.18, 2006.
   Google Scholar
• Pai R, Moore MR, Pilishvili T et al. Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. J. Infect. Dis.192, 1988–1995 (2005)
   PubMed Web of Science ®Google Scholar
• Flannery B, Heffernan RT, Harrison LH et al. Changes in invasive pneumococcal disease among HIV-infected adults living in an era of childhood pneumococcal immunization. Ann. Intern. Med.144, 1–9 (2006).
   Google Scholar
• Halasa N, Shankar S, Talbot T et al. Decreased incidence of invasive pneumococal disease in persons with sickle cell anemia. 43rd Annual Meeting of the Infectious Disease Society of America, CA, USA, October 5–9, 215, Abstract 299, 2005.
   Google Scholar
• Klugman K, Madhi S, Huebner R et al. A trial of 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N. Engl J. Med.349, 1341–1348 (2003).
   PubMed Web of Science ®Google Scholar
• Talbot TR, Poehling KA, Hartert TV et al. Reduction in high rates of antibiotic-nonsusceptible invasive pneumococcal disease in Tennessee after introduction of the pneumococcal conjugate vaccine. Clin. Infect. Dis.39, 641–648 (2004).
   PubMed Web of Science ®Google Scholar
• Stephens DS, Zughaier SM, Whitney CG et al. Incidence of macrolide resistance in Streptococcus pneumoniae after introduction of the pneumococcal conjugate vaccine: population-based assessment. Lancet365, 855–863 (2005).
   PubMed Web of Science ®Google Scholar
• Kyaw MH, Lynfield R, Schaffner W et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae.N. Engl J. Med.354(14), 1455–1463 (2006).
   Google Scholar
• Dagan R, Leibovitz E, Greenberg D, Yagupsky P, Fliss DM, Leiberman A. Dynamics of pneumococcal nasopharyngeal colonization during the first days of antibiotic treatment in pediatric patients. Pediatr. Infect. Dis. J.17, 880–85 (1998).
   PubMed Web of Science ®Google Scholar
• Moore MR, Hyde TB, Hennessy TW et al. Impact of a conjugate vaccine on community-wide carriage of nonsusceptible Streptococcus pneumoniae in Alaska. J. Infect. Dis.190, 2031–2038 (2004).
   PubMed Web of Science ®Google Scholar
• Huang SS, Platt R, Rifas-Shiman SL, Pelton SI, Goldmann D, Finkelstein JA. Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004. Pediatrics116, E408–E413 (2005).
   Google Scholar
• Klugman K. Efficacy of pneumococcal conjugate vaccines and their effect on carriage and antimicrobial resistance. Lancet Infect. Dis.1, 85–91 (2001).
   PubMedGoogle Scholar
• Black S, Shinefield H, Ling S et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr. Infect. Dis. J.21(9), 810–815 (2002).
   PubMed Web of Science ®Google Scholar
• Pneumonia Vaccine Trial Investigators’ Group. Standardization of interpretation of chest radiographs for the diagnosis of pneumonia in children. World Health Organization, Geneva, Switzerland 2001.
   Google Scholar
• Madhi S, Kuwanda L, Cutland C, Klugman KP. The impact of a 9-valent pneumococcal conjugate vaccine on the public health burden of pneumonia in HIV-infected and -uninfected children. Clin. Infect. Dis.40(10), 1511–1518 (2005).
   PubMed Web of Science ®Google Scholar
• Cutts FT, Zaman SM, Enwere G et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in the Gambia: randomised, double-blind, placebo-controlled trial. Lancet365, 1139–1146 (2005)
   PubMed Web of Science ®Google Scholar
• Mahdi SA, Klugman KP and the vaccine trialists group. A role for S treptococcus pneumoniae in virus-associated pneumonia. Nat. Med.10(8), 811–813 (2004).
   Google Scholar
• Nelson JC, Whitney CG, Yu O et al. Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia. 5th International Symposium on Pneumococci and Pneumococcal Diseases, Alice Springs, 2–6 April, 72, 72, Abstract SY4.05, 2006.
   Google Scholar
• Eskola J, Kilpi T, Palmu A et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N. Engl J. Med.344(6), 403–409 (2001).
   Google Scholar
• Black S, Shinefield H, Fireman B et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr. Infect. Dis. J.19(3), 187–195 (2000).
   PubMed Web of Science ®Google Scholar
• Palmu AA, Verho J, Jokinen J et al. The seven-valent pneumococcal conjugate vaccine reduces tympanostomy tube placement in children. Pediatr. Infect. Dis. J.23(8), 732–738 (2004).
   Google Scholar
• Kilpi T, Åhman H, Jokinen J et al. Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide–meningococcal outer membrane protein complex conjugate vaccine in 1666 children. Clin. Infect. Dis.37, 1155–1164 (2003).
   PubMed Web of Science ®Google Scholar
• Prymula R, Peeters P, Chrobok V et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniaeand non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet367, 740–748 (2006).
   PubMed Web of Science ®Google Scholar
• Poehling KA, Lafleur BJ, Szilagyi PG et al. Population-based impact of pneumococcal conjugate vaccine in young children. Pediatrics114, 755–761 (2004).
   Google Scholar
• Block SL, Hedrick J, Harrison CJ et al. Community-wide vaccination with the heptavalent pneumococcal conjugate significantly alters the microbiology of acute otitis media. Pediatr. Infect. Dis. J.23(9), 829–833 (2004).
   PubMed Web of Science ®Google Scholar
• Casey JR, Pichichero ME. Changes in frequency and pathogens causing acute ototis media in 1995–2003. Pediatr. Infect. Dis. J.23(9), 824–838 (2004).
   PubMed Web of Science ®Google Scholar
• Rennels MB, Edwards KM, Keyserling HL et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics101(4), 604–611 (1998).
   Google Scholar
• Huebner RE, Mbelle N, Forrest B, Madore DV, Klugman KP. Immunogenicity after one, two or three doses and impact on the antibody response to coadministered antigens of a nonavalent pneumococcal conjugate vaccine in infants in Soweto, South Africa. Pediatr. Infect. Dis. J.21(11), 1004–1007 (2002).
   PubMed Web of Science ®Google Scholar
• Sigurdardottir ST, Davidsdottir K, Arason VA, Jonsdottir O, Laudat F, Jonsdottir I. Safety and immunogenicity of CRM197 conjugated 9-valent pneumococcal and meningococcal C combination vaccine (9vPnCMnCC) administrated in two or three primary doses in infancy. 23rd Annual Meeting of the European Society for Paediatric Infectious Disease, Valencia, Spain, May 18–20, 202, Abtract 401, 2005.
   Google Scholar
• Lockhart S, Watson W, Fletcher P et al. Aluminum phosphate is an active adjuvant for CRM197 pneumococcal conjugate vaccine (PnC) in infants. Annual Vaccine Research Conference, MD, USA 2005.
   Google Scholar
• Goldblatt D, Southern J, Ashton L et al. Immunogenicity and boosting following a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers. Pediatr. Infect. Dis. J.25(4), 312–319 (2006)
   Google Scholar
• Käyhty H, Åhman H, Eriksson K, Sörberg M, Nilsson L. Immunogenicity and tolerability of a heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 12 months of age. Pediatr. Infect. Dis. J.24(2), 108–114 (2005).
   PubMed Web of Science ®Google Scholar
• Esposito S, Pugni L, Bosis S et al. Immunogenicity, safety and tolerability of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months post-natally to pre- and full-term infants. Vaccine23, 1703–1708 (2005).
   PubMed Web of Science ®Google Scholar
• Hausdorff WP, Bryant J, Paradiso PR, Siber GR. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, Part I. Clin. Infect. Dis.30, 100–121 (2000).
   PubMed Web of Science ®Google Scholar
• Whitney CG. Effect of pneumococcal conjugate vaccine on invasive disease in the US. 4th International Symposium on Pneumococci and Pneumococcal Diseases, Helsinki, Finland 2004.
   Google Scholar
• Mahon BE, Hsu K, Karumuri S, Kaplan SL, Mason EO, Pelton SI. Effectiveness of abbreviated and delayed 7-valent pneumococcal conjugate vaccine dosing regimens. Vaccine24, 2514–2520 (2006).
   Google Scholar
• Jones VF, Harrison C, Stout GG, Hopkins J. Nasopharyngeal colonization with heptavalent pneumococcal conjugate vaccine serotypes of Streptococcus pneumoniae with prolonged vaccine dosing intervals. Pediatr. Infect. Dis. J.24(11), 969–973 (2005).
   PubMedGoogle Scholar
• Ghaffar F, Barton T, Lozano J et al. Effect of the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniaein the first 2 years of life. Clin. Infect. Dis.39, 930–938 (2004).
   PubMed Web of Science ®Google Scholar
• Ramsay ME, McVernon J, Andrews NJ, Heath PT, Slack MP. Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method. J. Infect. Dis.188, 481–485 (2003).
   PubMed Web of Science ®Google Scholar
• Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet364, 365–367 (2004).
   PubMed Web of Science ®Google Scholar
• Kamerling JP. Pneumococcal polysaccharides: a chemical view. In: Streptococcus pneumoniae; Molecular biology and mechanisms of disease. Tomasz A (Ed.), Mary Ann Lieberrt Inc, NY, USA 81–114 (2000).
   Google Scholar
• Dagan R, Givon-Lavi N, Zamir O et al. Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers. J. Infect. Dis.185, 927–936 (2002).
   PubMed Web of Science ®Google Scholar
• Hicks LA, Flannery BL, Beall BW et al. Replacement pneumococcal disease: Increase in non-vaccine type disease in the era of widespread pneumococcal conjugate vaccination. Infectious Disease Society of America Annual Meeting, October 5–9, 202, Abstract 978, CA, USA 2005.
   Google Scholar
• Brueggemann AB, Pai R, Crook DW, Beall B. Nature’s experiment; Vaccine escape recombinants emerge after pneumococcal vaccination. 5th International Symposium on Pneumococci and Pneumococcal Diseases, Alice Springs, Australia, April 2–6, 78, Abstract SY5.05, 2006.
   Google Scholar
• Advisory Committee on Immunization Practices. Recommended Adult Immunization Schedule – United States, October 2005–September 2006. MMWR54(40), Q1–Q4 (2005).
   PubMedGoogle Scholar
• Shapiro ED, Berg AT, Austrian R et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N. Engl J. Med.325(21), 1453–1460 (1991).
   PubMed Web of Science ®Google Scholar
• Jackson LA, Benson P, Sneller VP et al. Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA281(3), 243–248 (1999).
   PubMed Web of Science ®Google Scholar
• Törling J, Hedlund J, Konradsen HB, Örtqvist Å. Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia. Vaccine22, 96–103 (2003).
   PubMed Web of Science ®Google Scholar
• De Roux A, Kuhnke A, Schmöle-Thoma B et al. Immunogenicity, safety and tolerability of a seven valent pneumococcal conjugate (7vPnC) and pneumococcal polysaccharide (23vPS) vaccine booster dose 12 months after first injection in elderly individuals. Infectious Disease Society of America Annual Meeting, CA, USA, October 5–9, 216, Abstract 980, 2005.
   Google Scholar